Clinical Trials Browser

Interventional × Gliosarcoma × Nivolumab × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Gliosarcoma

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT02311920 2023-01-10

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1 Completed

Gliosarcoma

NCT03014804 2020-07-24

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Withdrawn

Glioblastoma, Oligodendroglioma, Gliosarcoma